Cargando…
Antitumor activity of an anti‐CD98 antibody
CD98 is expressed on several tissue types and specifically upregulated on fast‐cycling cells undergoing clonal expansion. Various solid (e.g., nonsmall cell lung carcinoma) as well as hematological malignancies (e.g., acute myeloid leukemia) overexpress CD98. We have identified a CD98‐specific mouse...
Autores principales: | Hayes, Gregory M., Chinn, Lawrence, Cantor, Joseph M., Cairns, Belinda, Levashova, Zoia, Tran, Hoang, Velilla, Timothy, Duey, Dana, Lippincott, John, Zachwieja, Joseph, Ginsberg, Mark H., H. van der Horst, Edward |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680144/ https://www.ncbi.nlm.nih.gov/pubmed/25556716 http://dx.doi.org/10.1002/ijc.29415 |
Ejemplares similares
-
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
por: Schmieder, Roberta, et al.
Publicado: (2014) -
Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts
por: Koga, Yoshikatsu, et al.
Publicado: (2015) -
Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
por: Ott, Marion G, et al.
Publicado: (2012) -
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
por: Heiss, Markus M, et al.
Publicado: (2010) -
Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)